Shanghai
October 19, 2022
WuXi XDC, a world-leading bioconjugation drug CRDMO service company, announced that the company won the "Best CMO runner-up" in the "2022 World ADC Awards", which is also the first time WuXi XDC nominated for this honor. The
World ADC Awards are intended to recognize individuals or enterprises that are deeply engaged in the field of antibody-conjugated drugs (ADC), are committed to pioneering innovation, contributing to the long-term development of the ADC field, and bringing more innovative treatment solutions to patients. This year's candidates for various awards were nominated by more than 700 industry insiders, and WuXi United stood out with its far-reaching votes and was shortlisted for the finals.
Dr. Li Jincai, CEO of WuXi United, said, "We are honored to be recognized by the World ADC Award. This is not only a full recognition of WuXi United's United's United's United's United's United's United's United's United's United's United's United's United's United's United's people's United's United's United's United's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's people's It was held during the ADC Annual Meeting, and Dr. Li Jincai was invited to give a speech at the annual meeting. He introduced that WuXi United empowered the global ADC drug research and development process with an integrated discovery and development platform, shortening the timeline from DNA to new drug clinical trial application (IND) to within 15 months, leading the development of the industry. WuXi's integrated new drug discovery services include monoclonal antibody discovery and protein preparation, linker-payload synthesis, coupling research, and in vitro and in vitro experiments. WuXi United's integrated CMC development platform for antibody-conjugated drugs integrates multidisciplinary professional capabilities, close cooperation among internal teams and centralized GMP production, simplifies and efficiently help global customers develop high-quality drugs.
About WuXi XDC is a joint venture established by WuXi Biotechnology and Hequan Pharmaceutical. It focuses on providing end-to-end CRDMO services for bioconjugated drugs such as antibody-conjugated drugs (ADCs). Its services cover the research and development and production fields of antibodies and other conjugated biological drugs, linkers/chemical payloads, coupling stock solutions and preparations. WuXi United has successfully empowered multiple ADC drugs to complete clinical trial applications from DNA to new drug (IND) within 15 months, which is almost half shorter than traditional development time. As of June 30, 2022, WuXi United has signed 76 comprehensive projects with global customers, including 2 late clinical projects.
For more information, please visit: https://www.wuxibiologys.com/services-solutions/#XDC
Media Relations [email protected]
Business Inquiry [email protected]
